L’Aquila-based ExoLab Italia, a BioTech startup innovating the usage of plant-derived exosomes, has secured €5 million in a Sequence A funding spherical to speed up its industrial scale-up and worldwide enlargement
The spherical noticed funding from dsm-firmenich Ventures, CDP Enterprise Capital (by way of Fondo Acceleratori and Fondo Italia Enterprise II), Linfa Fund, managed by Riello Investimenti Sgr, and Maia Ventures.
“The funds raised will permit us to implement an bold strategic plan, which incorporates industrial scale-up, internationalisation and a decisive funding in human and territorial capital,” stated Gabriele Campi, CEO of ExoLab Italia.
ExoLab Italia was Co-founded in 2020 by Mariantonia Logozzi (CTO) and Stefano Fais (Scientific Director), each with in depth expertise on the Istituto Superiore di Sanità’s Division of Oncology and Molecular Drugs. Alongside them, Lorenzo Cilli (CFO) and Valerio Carconi (Head of Advertising and marketing & Gross sales) full the founding workforce.
The corporate initially secured backing from Scientifica Enterprise Capital, which has supported its development from the early phases and stays a key strategic companion.
ExoLab Italia is pioneering the usage of plant-derived exosomes—mobile vesicles obtained from fruit—to reinforce the effectiveness of elements utilized in cosmetics, prescription drugs, and nutraceuticals. With a proprietary know-how platform and a powerful R&D programme, the corporate goals to rework Italy’s wealthy natural agriculture sources into modern bioactive compounds for a number of industries.
With the brand new capital, ExoLab Italia plans to maneuver from its present 300 m² analysis and manufacturing facility to a brand new 1,000 m² plant in L’Aquila, considerably boosting manufacturing capability. This scale-up will help the corporate’s ambition to change into a number one world provider of plant exosome-based practical elements.
Alongside facility enlargement, the startup will even spend money on expertise acquisition, aiming to recruit 20 new staff over the following three years.
Traders see vital potential in ExoLab’s plant-derived exosome know-how, significantly in biomedical and wellness functions. “We’re significantly pleased with this partnership with ExoLab,” commented Alessandro Scortecci, Chief Direct Funding Officer of CDP Enterprise Capital Sgr. “Plant-derived exosomes are rising as a revolutionary frontier in biomedical applied sciences and sciences and, due to the superior analysis performed by the ExoLab workforce, they stand out as a possible sport changer within the beauty, nutraceutical and pharmaceutical sectors. Their extraordinary bioactive properties, mixed with excessive biocompatibility, make them excellent for creating modern functions aimed toward bettering well being and well-being, opening new horizons for ever-evolving markets.”
Trying forward, ExoLab Italia is about to push into worldwide markets, concentrating on key areas in Europe and past. The corporate goals to construct native partnerships and strengthen world model visibility.
Because it scales up, ExoLab will give attention to additional creating its analysis initiatives to increase the functions of plant-derived exosomes in well being and wellness.
